NCT06500065Recruiting
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 8 Jul 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Sarcoma
- NCT number
- NCT06500065
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 30 Sept 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
Other illness
- Hypersensitivity to somatostatin or similar peptides
- Patients with acute infections
Other
- Somatostatin long-acting analog in the past 6 months
- Patients who are pregnant or lactating
- Patients who are currently incarcerated
- Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)
Who the study is looking for
- Patients \>= 18 years of age
- Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies
- Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.